NOVARTIS for NOVARTIS
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
ACA Pharmaceutical Industry Fee Exclusions Orphan Drug Tax Mobile Workforce Thin Capitalization Rules 163(j) Base Erosion Surtax Tax Cuts & Jobs Act Implementation Innovation Box Expended FDII
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL CASSERLY | — |
| LEO A FARBER | — |
| JOSEPH MCGOWAN | — |
| SHELLY MUI-LIPNIK | — |
| SHAWN O'NEAIL | — |
Medicare/Medicaid MMM
H.R. 1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019 Biosimilars Medicare Part D Drug Pricing Part B Outcomes Based Contracts Generics Innovative Pharmaceuticals Cell and Gene Therapy Medicaid Alternative Payment Models
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR BOOTH | — |
| DANIEL CASSERLY | — |
| NORA CONNORS | — |
| LEO A FARBER | — |
| JOSEPH MCGOWAN | — |
| SHELLY MUI-LIPNIK | — |
| SHAWN O'NEAIL | — |
Trade (domestic/foreign) TRD
Free Trade Agreements - Intellectual Property and Transparency Provisions - Free Trade Agreements Access to Medicines Issues Global Health Issues India, China and Canada IP and Market Access Issues Sub-standards Medicines Quality of Medicines International Market Access and Intellectual Property Issues Biopharmaceutical Innovation Policies Columbia Intellectual Property Regulatory Cooperation The North American Free Trade Agreement - NAFTA Re-negotiation USTR Special 301 Report/National Trade Estimate Trade Policy KORUS Tariffs CFIUS
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LEO A FARBER | — |
| SARAH HALLER | — |
| JOSEPH MCGOWAN | — |
| SHELLY MUI-LIPNIK | — |
| SHAWN O'NEAIL | — |
Copyright/Patent/Trademark CPT
S.659 - Biologic Patent Transparency Act Data Exclusivity Trade Secrets Intellectual Property Biopharmaceutical Innovation Policy Issues Biologics Data Protection issues Patent Litigation Reform and Issues Related to Post Grant Proceedings at PTO Neonates BPCIA Hatch-Waxman Patents Inter Partes Review at PTO Biosimilars
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR BOOTH New | — |
| DANIEL CASSERLY | — |
| NORA CONNORS | — |
| LEO A FARBER | — |
| JOSEPH MCGOWAN | — |
| SHELLY MUI-LIPNIK | — |
| SHAWN O'NEAIL | — |
Health Issues HCR
HR 938: Bringing Low-Cost Options and Competition while Keeping Incentives for New Generics Act HR 1520: Purple Book Continuity Act HR 1503: Orange Book Transparency Act HR 1499: Protecting Consumer Access to Generic Drugs Act HR 2113:Speeding Access to Already Approved Pharmaceuticals Act of 2017 Senate SPIKE Act Fast Generics Cell & Gene Therapy, including reimbursement 340B Drug Discount Program Drug Importation REMS Creates Act Value of Medicines Drug Cost/Pricing Biosimilars Reimbursement Outcomes based Contracting Part D Non-interference Orphan Drugs Drug Pricing Transparency Clinical Trials Virtual Clinical Trials Part D Donut Hole Biosimilar Pass Through Payments Value Based Pricing
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR BOOTH | — |
| DANIEL CASSERLY | — |
| NORA CONNORS | — |
| LEO A FARBER | — |
| SARAH HALLER | — |
| JOSEPH MCGOWAN | — |
| SHELLY MUI-LIPNIK | — |
| SHAWN O'NEAIL | — |
Foreign Relations FOR
Foreign Investment Risk Review Modernization Act of 2017 (FIRMMA) CFIUS Reform Foreign Agents Registration Act (FARA) Reform Treasury
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LEO A FARBER | — |
| JOSEPH MCGOWAN | — |
| SHELLY MUI-LIPNIK | — |
| SHAWN O'NEAIL | — |
Budget/Appropriations BUD
FDA Appropriations funding for Generic Drugs Certified Importer Program (CIP) Reconciliation Gx Drug Labeling Biosimilars Importation Drug Pricing Value of Meds
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL CASSERLY | — |
| NORA CONNORS | — |
| LEO A FARBER | — |
| JOSEPH MCGOWAN | — |
| SHELLY MUI-LIPNIK | — |
| SHAWN O'NEAIL | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.